10-23-2015, 09:12 AM
AbbVie is something that was on the back of my mind to research, but even though Im tempted - Im not ready to buy in without doing my due diligence. GILD is benefiting a lot with ABBV's fall since that will boost their HepC drug instead.
I own JNJ as well and to complement, I own AMGN - which has more of a focus on inflammation, oncology and nephrology drugs.
FYI, GILD's focus is on HepC and HIV drugs.
I own JNJ as well and to complement, I own AMGN - which has more of a focus on inflammation, oncology and nephrology drugs.
FYI, GILD's focus is on HepC and HIV drugs.